Hepatic Carcinoma Clinical Trial
Official title:
Development of a Neuronal Microscope for Cell Characterization and Manipulation (Neuronal micRoscopy for cEll Behavioral Examination and mAnipuLation)
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and is a leading cause of cancer-related death worldwide. The prognosis of HCC remains poor, with a 5-year survival rate of 18%. Risk factors for HCC include viral infection, autoimmune hepatitis, chronic alcohol use or metabolic fatty liver disease, obesity, and diabetes mellitus.
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and is a leading cause of cancer-related death worldwide. The prognosis of HCC remains poor, with a 5-year survival rate of 18%. Risk factors for HCC include viral infection, autoimmune hepatitis, chronic alcohol use or metabolic fatty liver disease, obesity, and diabetes mellitus. Furthermore, alterations and chronic inflammation of the microenvironment can facilitate the transformation of normal liver stem cells into precancerous tumor stem cells. All these underlying pathogenic stimuli can induce a spectrum of genetic and epigenetic modifications, which are involved in the cell cycle, cell growth and regulation of adhesion. Therefore, heterogeneity and tumor priming potential arise from a combination of both endogenous and exogenous factors. However, current in vitro models, based on conventional hepatoma and hepatocarcinoma cell lines, fail to recapitulate key characteristics of tumor tissue such as three-dimensional tissue architecture, cellular heterogeneity, and cell-cell interactions. Organoids, which are 3D cellular structures generated from induced pluripotent stem cells and adult tissue-resident stem cells, have recently been exploited to overcome the limitations of 2D cell culture systems, emerging as powerful tools for studying human diseases. Therefore, organoid structures stably preserve the genetic information of autologous tissue by mimicking the pathological state of the tissue itself. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03253250 -
The Investigation of Peginterferon Alfa-2a on the RFS of the Subjects With HCC Who Have Been Treated by Resection
|
Phase 4 | |
Terminated |
NCT01760616 -
Huaier Granule for Prevention of Disease Progression of Hepatocarcinoma After Non-radical Hepatectomy
|
Phase 4 | |
Active, not recruiting |
NCT04682847 -
Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers
|
||
Not yet recruiting |
NCT03149523 -
Exhaustive Genetic and Immunological Characterization of Colon, Kidney and Liver Tumors
|
N/A | |
Recruiting |
NCT05009550 -
ESP Block on Patient Outcomes in Patients With Liver Tumor Undergoing Radiofrequency Ablation
|
N/A | |
Recruiting |
NCT06342414 -
An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer
|
||
Recruiting |
NCT03132740 -
Impact of Three-dimensional Visualization on Operation Strategy and Complications for Complex Hepatic Carcinoma
|
||
Completed |
NCT03164382 -
Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil/Leucovorin Versus Sorafenib in Advanced Hepatocellular Carcinoma
|
Phase 3 | |
Completed |
NCT03572582 -
Transarterial Chemoembolization in Combination With Nivolumab Performed for Intermediate Stage Hepatocellular Carcinoma
|
Phase 2 | |
Completed |
NCT04266548 -
Arterial Base Fluorescence Segmental Positive Staining
|
N/A | |
Recruiting |
NCT03013712 -
A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT01350726 -
Functional-three-dimensional Reconstruction of Liver by 99MTc-GSA-SPECT Scan
|
N/A | |
Completed |
NCT06245798 -
Liver Resection for Patients With Hepatocellular Carcinoma and Clinically Significant Portal Hypertension
|
||
Recruiting |
NCT04220944 -
Combined Locoregional Treatment With Immunotherapy for Unresectable HCC.
|
Phase 1 | |
Completed |
NCT02332551 -
Percutaneous Irreversible Electroporation to Treat Liver Cancer Close to the Gallbladder
|
N/A | |
Completed |
NCT02352935 -
Percutaneous Irreversible Electroporation for Unresectable Hepatic Carcinoma in Poor Liver Function
|
N/A | |
Completed |
NCT02834780 -
Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma
|
Phase 1 | |
Not yet recruiting |
NCT06182865 -
A Study of Ga-68 Dolacga to Evaluate Liver Reserve Function in Patients With HCC Before and After Proton Therapy
|
N/A | |
Completed |
NCT05007548 -
to Assess the Accuracy and Reliability of the Ga68-Dolacga Positron Emission Tomography Compared to Computer Tomography Volumetry and Indocyanine Green Retention Test for Measurement of Liver Reserve
|
Phase 2 | |
Completed |
NCT03163186 -
Transradial Versus Transfemoral Arterial Access in Liver Cancer Embolization: Randomized Trial to Assess Patient Outcomes and Satisfaction (BEST ACCESS Trial).
|
N/A |